Neurelis

Neurelis is a private, commercial-stage biopharmaceutical company specializing in neurology, with a core focus on epilepsy. The company has built its portfolio around proprietary drug delivery enhancement technologies—Intravail®, ProTek®, and Hydrogel™—which enable non-invasive administration of therapeutics. Its lead commercial product is Valtoco® (diazepam nasal spray) for acute treatment of seizure clusters, and it maintains a pipeline of investigational neurology candidates. Neurelis operates with a patient-centric model, offering savings and support programs to ensure access to its therapies.

Proprietary drug delivery and stabilization technologies including Intravail® (transmucosal absorption enhancer), ProTek® (stabilization), and Hydrogel™ (controlled release), designed for non-invasive delivery of peptides, proteins, and small molecules.

In acute seizure treatment, Neurelis's Valtoco® competes directly with UCB's Nayzilam® (midazolam nasal spray) and Bausch Health's Diastat® (diazepam rectal gel). The competitive landscape emphasizes convenience, reliability, and speed of administration. The company's technology platform also positions it against other drug delivery specialty firms, competing on the basis of enhancement efficacy and breadth of molecule applicability.